PAUL L. HALLENBECK — FOUNDER, PRESIDENT AND CHIEF SCIENTIFIC OFFICER

Dr. Hallenbeck is the Founder, President and Chief Scientific Officer of Seneca Therapeutics.  He is a multiple award winning, serial entrepreneur who has dedicated over 30 years of research to provide a treatment for patients with the most aggressive therapeutic-resistant solid cancers. Dr. Hallenbeck has R&D expertise in all phases of cancer immuno-therapeutics. Prior to Seneca Therapeutics, he was the sole founder of Neotropix, where he raised $30M in VC, then successfully led SVV (NTX-001) through IND approval, and completed several Phase I/II clinical trials, establishing an excellent safety record & compelling evidence of efficacy. Dr. Hallenbeck earned his PhD in Microbiology from the University of Illinois-Urbana.

GAVIN MAITLAND - INTERIM CHIEF FINANCIAL OFFICER

Mr. Maitland is the Chief Financial Officer of Seneca Therapeutics. He is a seasoned finance executive and CFO with over 30 years in corporate finance and accounting leadership roles in Europe and the United States, including over 20 years in life sciences. He adopts a hands-on approach to problem-solving, brings clarity and transparency to financial information, and is a highly regarded business advisor.  Gavin is a PricewaterhouseCoopers alumnus, a chartered accountant (ICAS), and holds an MBA from London Business School.  Gavin is based in Boston, MA.

Janice Ingram — BUSINESS OPERATIONS AND EXECUTIVE ASSISTANT, RESEARCH & DEVELOPMENT

As Business Operations and Executive Assistant, Research & Development for Seneca, Ms. Ingram is responsible for the R&D budgetary forecast and project management of R&D studies and spending. She has over 20 years of Human Resource Management with a concentration in Corporate Governance and Equity Incentive Plan Design and Implementation. She collaborated with Dr. Hallenbeck at Neotropix where they successfully led a team of 15 scientists in a GMP facility/vivarium and completed many pre-clinical studies to support the first-in-human clinical trial using SVV-001 as an immunotherapeutic treatment for cancer. Seneca Therapeutics has an open IND to begin a clinical trial in early 2025.

HUNG V. TRINH - SENIOR VICE PRESIDENT OF OPERATIONS

Dr. Trinh has over 15 years in various functions such as Research and Development, Assay Development, Technical Operations, CMC, cGMP Manufacturing, and Global Lead of Business Alliance. Dr. Trinh has significant experience in both clinical and commercial operations, specializing for API - fermentation, vaccine, biologics, viral vectors, oncolytic virus Adenovirus and VSV, and cell therapy. Prior to joining Seneca Therapeutics, Dr. Trinh was a consultant to the Department of U.S. Defense, WRAIR, and non-profit organization Henry M. Jackson Foundation to lead viral and bacterial vaccine development (process development for recombinant proteins, monoclonal antibodies and assay development) from pre-clinical (discovery phase and lead candidates) to clinical development (phase 1, 2, and 3) for over 10 clinical trial programs with global operations (USA, Asia, EU, Middle East, and Africa), which has resulted over 30 peer-reviewed publications.

Sarath Kanekal —Vice President of Regulatory Affairs

Dr. Kanekal, DVM, PhD, DABT, RAC is a Board Certified Regulatory Affairs Professional experienced in both early & late stage NDA & 505b2 filings. He has a track record of FAST successful INDs—5-6 months from candidate nomination to FDA ‘hold’ resolutions. He has represented sponsors at various stages: preIND, EOPII, pre-NDA & Advisory Committee meetings. He has a sound understanding of US and European Regulatory requirements based on real-life hands on experience: FDA, CDER, CBER, EMEA, BfARM, AFSSAPS, MHRA etc. He has also authored regulatory documents, briefing documents, investigator brochures, clinical protocols, and annual reports.

MICHAEL J. LACY — vice president of immunology

Dr. Michael Lacy has an exquisite background in Zoology, Botany, Microbiology and Immunology. Dr. Lacy is involved in Seneca Therapeutics multiple IV program. Dr. Michael Lacy received his Ph.D. in Immunology from the University of Illinois at Urbana Champaign and completed his post doc in the Dept. of Biochemistry performing genetic analyses of mouse T cell receptors.  He is a Senior Immunology Consultant at Seneca Therapeutics where his focus is on the development of immunotherapy regimens utilizing the oncolytic Seneca Valley Virus (SVV-001) and arming SVV with therapeutic genes.  Prior to his engagement with Seneca Therapeutics, Dr. Lacy was Director of Non-Clinical Immunology at Emergent BioSolutions where he successfully advanced research grade vaccines and their formulations for anthrax, Chlamydia, Ebola, Zika, Influenza and others, and most recently a universal flu vaccine and an improved anthrax vaccine.  

Neil Sankar — Chief Medical Officer 

Dr. Sankar, MD, MPH, CCRP is the Chief Medical Officer of Seneca Therapeutics.  He is President & Founder of SwanBio, LLC, a BD & Clinical Strategy consultancy firm that facilitates the translation of scientific discoveries into cancer therapeutics. An expert in global clinical development & regulatory strategies for therapeutic drugs; he has led numerous clinical trials in oncology (Genentech & Pharmacyclics) therapy ranging from breast, ovarian, pancreatic, liver, lung, and connective tissue tumors, to a range of hematological malignancies.

Igor Puzanov, MD, MSci, FAACP

Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

In his professional career, he has worked on developing precision medicine agents as well as immunotherapies. In the first in human trial of PLX4032/vemurafenib we provided critical PK/PD data that led to the first in class/ first in human FDA- approved BRAF inhibitor. His team was instrumental in the development of talimogene laherparepvec, the first in human oncolytic virus therapy for patients with melanoma. Recently, he has explored immunotherapy combinations with targeted agents as well as combinations of oncolytic viruses with checkpoint inhibitors.

E. Antonio Chiocca, MD, PhD

Chair, Department of Neurosurgery, Harvard Medical School

Dr. Chiocca’s research has focused on how viruses with specific gene mutations will replicate selectively in tumors with a specific defect in a tumor suppressor pathway. His research has also included how modulation of innate immunity will improve replication of these tumor-selective viruses. More recently, Dr. Chiocca has elucidated how specific microRNAs (mir128 and mir451) regulate cellular target transcripts to permit tumor cell self-renewal and invasion into brain. He also has been the principal investigator of three multi-institutional clinical trials of gene-, viral-therapies for malignant gliomas and has been a permanent member of NIH study sections (NCI DT and NCI P01-D clinical studies).

Dr. Zachary Morris

Department of Human Oncology at The University of Wisconsin School of Medicine and Public Health

As a physician-scientist, his current clinical focus is on the treatment of patients with melanoma and soft tissue sarcomas. His independent translational research laboratory focuses on the mechanisms whereby radiation may enhance the response to immunotherapies.